PGR and breast carcinoma: Given the lack of reliable results obtained with commercially available antibodies against SGK1, we analyzed the expression of pNDRG1 (T346) in 273 breast invasive carcinomas, comprising 138 triple-negative breast cancer (TNBC), 68 estrogen-/progesterone-receptor-positive, and 67 human epidermal growth factor 2 (HER2)-positive breast cancer patients.